drugset / Trial / NCT05100719

The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)

NCT05100719

Not yet recruiting 200 enrolled University of Pecs
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Irritable bowel syndrome (IBS) is a functional gastrointestinal disease. There is no well-defined pharmacological treatment. This clinical trial is a prospective, double-blind, two-armed randomized controlled, single-center trial. It is created to examine the role of IBS in patients with lactose intolerance. IBS patients undergo lactose H2 breath test (LHBT) and lactose tolerance test (LTT). Those with positive LTT and LHBT will be randomized into two groups: alverine-citrate + simethicone and lactase group (1) or alverin-citrate + simethicone with the placebo group (2). The goal of this study is to compare the lactase enzyme with placebo in IBS patients with lactose intolerance.

Timeline

Start
2022-09
Primary completion
2026-09
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator lactase Protein / enzyme biologic
Comparator Alverine Small molecule
Comparator Simethicone Other / unclassified